Jerry St Peter to spearhead NicOx expansion in US
Aims to build an international ophthalmology company
St Peter has extensive knowledge of the ophthalmology market in the US. Most recently, he developed the commercial unit of Inspire Pharmaceuticals, an ophthalmology focused company acquired by Merck & Co for US$430m in May 2011.
In collaboration with NicOx’s European headquarters, St Peter will be responsible for identifying and evaluating North American opportunities that can be exploited globally to build NicOx’s late-stage ophthalmic portfolio. He will also lead the development of NicOx’s US ophthalmology business.
NicOx announced earlier this week that it had acquired 11.8% of the shares of Altacor, a privately held ophthalmology company based in the UK, and entered into an exclusive option agreement to acquire the remaining shares.
Michele Garufi, chairman and ceo of NicOx, said: ‘Jerry has been working with NicOx as a consultant for the past five months, helping us in the ongoing evaluation of a number of ophthalmology companies and products. He will be a key asset in the creation and future expansion of our presence in the US as we work towards delivering our strategy of building an international ophthalmology company.’
St Peter joined Inspire in 2003 and held the positions of senior vice president, Ophthalmology Business Unit, svp, sales and managed markets and vp of sales.
Prior to joining Inspire, St Peter held a number of leadership positions for Muro Pharmaceutical, a private ophthalmic, pulmonary, asthma and allergy specialist pharmaceutical company.
You may also like
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Regulatory
The key role of IVDs in healthcare: challenges to commercialisation and access
In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
